Search

Your search keyword '"Chong, Lee-Won"' showing total 136 results
Start Over Author "Chong, Lee-Won"
136 results on '"Chong, Lee-Won"'

1. Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan

Author

Chang, Chin-Wei, Hsu, Wei-Fan, Tseng, Kuo-Chih, Chen, Chi-Yi, Cheng, Pin-Nan, Hung, Chao-Hung, Lo, Ching-Chu, Bair, Ming-Jong, Chen, Chien-Hung, Lee, Pei-Lun, Lin, Chun-Yen, Kuo, Hsing-Tao, Chen, Chun-Ting, Yang, Chi-Chieh, Huang, Jee-Fu, Tai, Chi-Ming, Hu, Jui-Ting, Lin, Chih-Lang, Su, Wei-Wen, Tsai, Wei-Lun, Huang, Yi-Hsiang, Cheng, Chien-Yu, Lin, Chih-Lin, Wang, Chia-Chi, Yang, Sheng-Shun, Mo, Lein-Ray, Chen, Guei-Ying, Chang, Chun-Chao, Wang, Szu-Jen, Huang, Chia-Sheng, Hsieh, Tsai-Yuan, Lin, Chih-Wen, Lee, Tzong-Hsi, Chong, Lee-Won, Huang, Chien-Wei, Chang, Shiuh-Nan, Tsai, Ming-Chang, Hsu, Shih-Jer, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Lin, Han-Chieh, Tsai, Pei-Chien, Yeh, Ming-Lun, Huang, Chung-Feng, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Peng, Cheng-Yuan

Published
2024
Full Text
View/download PDF

2. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan

Author

Yang, Chun-Chi, Huang, Chung-Feng, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Kuo, Hsing-Tao, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Tseng, Kuo-Chih, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2024
Full Text
View/download PDF

3. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan

Author

Yu, Ming-Lung, Tai, Chi‐Ming, Mo, Lein-Ray, Kuo, Hsing-Tao, Huang, Chung-Feng, Tseng, Kuo-Chih, Lo, Ching-Chu, Bair, Ming-Jong, Wang, Szu-Jen, Huang, Jee-Fu, Yeh, Ming-Lun, Chen, Chun-Ting, Tsai, Ming-Chang, Huang, Chien-Wei, Lee, Pei-Lun, Yang, Tzeng-Hue, Huang, Yi-Hsiang, Chong, Lee-Won, Chen, Chien-Lin, Yang, Chi-Chieh, Hung, Chao-Hung, Yang, Sheng‐Shun, Cheng, Pin-Nan, Hsieh, Tsai-Yuan, Hu, Jui-Ting, Wu, Wen-Chih, Cheng, Chien-Yu, Chen, Guei-Ying, Zhou, Guo-Xiong, Tsai, Wei-Lun, Kao, Chien-Neng, Lin, Chih-Lang, Wang, Chia-Chi, Lin, Ta-Ya, Lin, Chih‐Lin, Su, Wei-Wen, Lee, Tzong-Hsi, Chang, Te-Sheng, Liu, Chun-Jen, Dai, Chia-Yen, Chen, Chi-Yi, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wan-Long, and Peng, Cheng-Yuan

Published
2024
Full Text
View/download PDF

4. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry

Author

Chang, Te-Sheng, Huang, Chung-Feng, Kuo, Hsing-Tao, Lo, Ching-Chu, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Chen, Chi-Yi, Tseng, Kuo-Chih, Hung, Chao-Hung, and Yu, Ming-Lung

Published
2023
Full Text
View/download PDF

5. THU-365 Real-world effectiveness and safety of 8-week glecaprevir/ pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry

Author

Huang, Chung-Feng, primary, Chang, Te-Sheng, additional, Kuo, Hsing-Tao, additional, Huang, Chien-Wei, additional, Mo, Lien-Ray, additional, Tai, Chi-Ming, additional, Tseng, Kuo-Chih, additional, Bair, Ming-Jong, additional, Wang, Sih-Ren, additional, Lo, Ching-Chu, additional, Chong, Lee-Won, additional, Cheng, Pin-Nan, additional, Yeh, Ming-Lun, additional, Peng, Cheng-Yuan, additional, Cheng, Chien-Yu, additional, Huang, Jee-Fu, additional, Lin, Chih-Lang, additional, Yang, Chi-Chieh, additional, Hsieh, Tsai-Yuan, additional, Lee, Tzong-Hsi, additional, Lee, Pei-Lun, additional, Wu, Wen-Chih, additional, Lin, Chih-Lin, additional, Su, Wei-Wen, additional, Yang, Sheng-Shun, additional, Wang, Chia-Chi, additional, Hu, Jui-Ting, additional, Chen, Chun-Ting, additional, Huang, Yi-Hsiang, additional, Chang, Chun-Chao, additional, Huang, Chia-Sheng, additional, Chen, Guei-Ying, additional, Kao, Chien-Neng, additional, Liu, Chun-Jen, additional, Lee, Mei-Hsuan, additional, Tsai, Pei-Chien, additional, Dai, Chia-Yen, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wan-Long, additional, Hung, Chao-Hung, additional, Chen, Chi-Yi, additional, and Yu, Ming-Lung, additional

Published
2024
Full Text
View/download PDF

6. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan

Author

Lo, Ching-Chu, Huang, Chung-Feng, Cheng, Pin-Nan, Tseng, Kuo-Chih, Chen, Chi-Yi, Kuo, Hsing-Tao, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Chen, Chien-Hung, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, Chang, Te Sheng, Huang, Jee-Fu, Yang, Chi-Chieh, Hu, Jui-Ting, Lin, Chih-Wen, Chen, Chun-Ting, Wang, Chia-Chi, Su, Wei-Wen, Hsieh, Tsai-Yuan, Lin, Chih-Lin, Tsai, Wei-Lun, Lee, Tzong-Hsi, Chen, Guei-Ying, Wang, Szu-Jen, Chang, Chun-Chao, Mo, Lein-Ray, Yang, Sheng-Shun, Wu, Wen-Chih, Huang, Chia-Sheng, Hsiung, Chou-Kwok, Kao, Chien-Neng, Tsai, Pei-Chien, Liu, Chen-Hua, Lee, Mei-Hsuan, Liu, Chun-Jen, Dai, Chia-Yen, Chuang, Wan-Long, Lin, Han-Chieh, Kao, Jia-Horng, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

7. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)

Author

Huang, Chung-Feng, Tseng, Kuo-Chih, Cheng, Pin-Nan, Hung, Chao-Hung, Lo, Ching-Chu, Peng, Cheng-Yuan, Bair, Ming-Jong, Yeh, Ming-Lun, Chen, Chien-Hung, Lee, Pei-Lun, Lin, Chun-Yen, Kuo, Hsing-Tao, Chen, Chun-Ting, Yang, Chi-Chieh, Huang, Jee-Fu, Tai, Chi-Ming, Hu, Jui-Ting, Lin, Chih-Lang, Su, Wei-Wen, Tsai, Wei-Lun, Huang, Yi-Hsiang, Cheng, Chien-Yu, Lin, Chih-Lin, Wang, Chia-Chi, Yang, Sheng-Shun, Mo, Lein-Ray, Chen, Guei-Ying, Chang, Chun-Chao, Wang, Szu-Jen, Huang, Chia-Sheng, Hsieh, Tsai-Yuan, Lin, Chih-Wen, Lee, Tzong-Hsi, Chong, Lee-Won, Huang, Chien-Wei, Chang, Shiuh-Nan, Tsai, Ming-Chang, Hsu, Shih-Jer, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Lin, Han-Chieh, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Chuang, Wan-Long, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

8. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan

Author

Cheng, Pin-Nan, Mo, Lein-Ray, Chen, Chun-Ting, Chen, Chi-Yi, Huang, Chung-Feng, Kuo, Hsing-Tao, Lo, Ching-Chu, Tseng, Kuo-Chih, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Chen, Chien-Hung, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, Chang, Te Sheng, Huang, Jee-Fu, Yang, Chi-Chieh, Hu, Jui-Ting, Lin, Chih-Wen, Wang, Chia-Chi, Su, Wei-Wen, Hsieh, Tsai-Yuan, Lin, Chih-Lin, Tsai, Wei-Lun, Lee, Tzong-Hsi, Chen, Guei-Ying, Wang, Szu-Jen, Chang, Chun-Chao, Yang, Sheng-Shun, Wu, Wen-Chih, Huang, Chia-Sheng, Chou, Kwok-Hsiung, Kao, Chien-Neng, Tsai, Pei-Chien, Liu, Chen-Hua, Lee, Mei-Hsuan, Cheng, Chien-Yu, Tsai, Ming-Chang, Liu, Chun-Jen, Dai, Chia-Yen, Lin, Han-Chieh, Kao, Jia-Horng, Chuang, Wan-Long, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

10. The benefits of hepatitis C viral eradication: a real-world nationwide cohort study in Taiwan

Author

Chang, Chin-Wei, primary, Hsu, Wei-Fan, additional, Tseng, Kuo-Chih, additional, Chen, Chi-Yi, additional, Cheng, Pin-Nan, additional, Hung, Chao-Hung, additional, Lo, Ching-Chu, additional, Bair, Ming-Jong, additional, Chen, Chien-Hung, additional, Lee, Pei-Lun, additional, Lin, Chun-Yen, additional, Kuo, Hsing-Tao, additional, Chen, Chun-Ting, additional, Yang, Chi-Chieh, additional, Huang, Jee-Fu, additional, Tai, Chi-Ming, additional, Hu, Jui-Ting, additional, Lin, Chih-Lang, additional, Su, Wei-Wen, additional, Tsai, Wei-Lun, additional, Huang, Yi-Hsiang, additional, Cheng, Chien-Yu, additional, Lin, Chih-Lin, additional, Wang, Chia-Chi, additional, Yang, Sheng-Shun, additional, Mo, Lein-Ray, additional, Chen, Guei-Ying, additional, Chang, Chun-Chao, additional, Wang, Szu-Jen, additional, Huang, Chia-Sheng, additional, Hsieh, Tsai-Yuan, additional, Lin, Chih-Wen, additional, Lee, Tzong-Hsi, additional, Chong, Lee-Won, additional, Huang, Chien-Wei, additional, Chang, Shiuh-Nan, additional, Tsai, Ming-Chang, additional, Hsu, Shih-Jer, additional, Kao, Jia-Horng, additional, Liu, Chun-Jen, additional, Liu, Chen-Hua, additional, Lin, Han-Chieh, additional, Tsai, Pei-Chien, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Yu, Ming-Lung, additional, and Peng, Cheng-Yuan, additional

Published
2024
Full Text
View/download PDF

11. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

Author

Huang, Chung-Feng, Kuo, Hsing-Tao, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Chen, Chi-Yi, Tseng, Kuo-Chih, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

12. Artificial intelligence predicts direct-acting antivirals failure among HCV patients: A Nationwide HCV Registry Program

Author

Lu, Ming-Ying, primary, Huang, Chung-Feng, additional, Hung, Chao-Hung, additional, Tai, Chi‐Ming, additional, Mo, Lein-Ray, additional, Kuo, Hsing-Tao, additional, Tseng, Kuo-Chih, additional, Lo, Ching-Chu, additional, Bair, Ming-Jong, additional, Wang, Szu-Jen, additional, Huang, Jee-Fu, additional, Yeh, Ming-Lun, additional, Chen, Chun-Ting, additional, Tsai, Ming-Chang, additional, Huang, Chien-Wei, additional, Lee, Pei-Lun, additional, Yang, Tzeng-Hue, additional, Huang, Yi-Hsiang, additional, Chong, Lee-Won, additional, Chen, Chien-Lin, additional, Yang, Chi-Chieh, additional, Yang, Sheng‐Shun, additional, Cheng, Pin-Nan, additional, Hsieh, Tsai-Yuan, additional, Hu, Jui-Ting, additional, Wu, Wen-Chih, additional, Cheng, Chien-Yu, additional, Chen, Guei-Ying, additional, Zhou, Guo-Xiong, additional, Tsai, Wei-Lun, additional, Kao, Chien-Neng, additional, Lin, Chih-Lang, additional, Wang, Chia-Chi, additional, Lin, Ta-Ya, additional, Lin, Chih‐Lin, additional, Su, Wei-Wen, additional, Lee, Tzong-Hsi, additional, Chang, Te-Sheng, additional, Liu, Chun-Jen, additional, Dai, Chia-Yen, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wan-Long, additional, Peng, Cheng-Yuan, additional, Tsai, Chun-Wei-, additional, Chen, Chi-Yi, additional, and Yu, Ming-Lung, additional

Published
2023
Full Text
View/download PDF

14. The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry

Author

Huang, Chung-Feng, primary, Kuo, Hsing-Tao, additional, Chang, Te-Sheng, additional, Lo, Ching-Chu, additional, Hung, Chao-Hung, additional, Huang, Chien-Wei, additional, Chong, Lee-Won, additional, Cheng, Pin-Nan, additional, Yeh, Ming-Lun, additional, Peng, Cheng-Yuan, additional, Cheng, Chien-Yu, additional, Huang, Jee-Fu, additional, Bair, Ming-Jong, additional, Lin, Chih-Lang, additional, Yang, Chi-Chieh, additional, Wang, Sih-Ren, additional, Hsieh, Tsai-Yuan, additional, Lee, Tzong-Hsi, additional, Lee, Pei-Lun, additional, Wu, Wen-Chih, additional, Lin, Chih-Lin, additional, Su, Wei-Wen, additional, Yang, Shengshun, additional, Wang, Chia-Chi, additional, Hu, Jui-Ting, additional, Mou, Lien-Juei, additional, Chen, Chun-Ting, additional, Huang, Yi-Hsiang, additional, Chang, Chun-Chao, additional, Huang, Jia-Sheng, additional, Chen, Guei-Ying, additional, Gao, Jian-Neng, additional, Tai, Chi-Ming, additional, Liu, Chun-Jen, additional, Lee, Mei-Hsuan, additional, Tsai, Pei-Chien, additional, Dai, Chia-Yen, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wan-Long, additional, Chen, Chiyi, additional, Tseng, Kuo-Chih, additional, and Yu, Ming-Lung, additional

Published
2023
Full Text
View/download PDF

15. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan

Author

Yu, Ming-Lung, primary, Tai, Chi-Ming, additional, Mou, Lien-Juei, additional, Kuo, Hsing-Tao, additional, Huang, Chung-Feng, additional, Tseng, Kuo-Chih, additional, Lo, Chingchu, additional, Bair, Ming-Jong, additional, Wang, Sih-Ren, additional, Huang, Jee-Fu, additional, Yeh, Ming-Lun, additional, Chen, Chun-Ting, additional, Tsai, Ming-Chang, additional, Huang, Chien-Wei, additional, Lee, Pei-Lun, additional, Yang, Tzeng-Hue, additional, Huang, Yi-Hsiang, additional, Chong, Lee-Won, additional, Chen, Chien-Lin, additional, Yang, Chi-Chieh, additional, Hung, Chao-Hung, additional, Yang, Sheng-Shun, additional, Cheng, Pin-Nan, additional, Hsieh, Tsai-Yuan, additional, Hu, Jui-Ting, additional, Wu, Wen-Chih, additional, Cheng, Chien-Yu, additional, Chen, Guei-Ying, additional, Chou, Kwok-Hsiung, additional, Tsai, Wei-lun, additional, Gao, Jian-Neng, additional, Lin, Chih-Lang, additional, Wang, Chia-Chi, additional, Lin, Ta-Ya, additional, Lin, Chih-Lin, additional, Su, Wei-Wen, additional, Lee, Tzong-Hsi, additional, Chang, Te-Sheng, additional, Liu, Chun-Jen, additional, Dai, Chia-Yen, additional, Chen, Chi-Yi, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wan-Long, additional, and Peng, Cheng-Yuan, additional

Published
2023
Full Text
View/download PDF

16. THU-174 - The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry

Author

Huang, Chung-Feng, Kuo, Hsing-Tao, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Sih-Ren, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Shengshun, Wang, Chia-Chi, Hu, Jui-Ting, Mou, Lien-Juei, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Jia-Sheng, Chen, Guei-Ying, Gao, Jian-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wan-Long, Chen, Chiyi, Tseng, Kuo-Chih, and Yu, Ming-Lung

Published
2023
Full Text
View/download PDF

17. Serum adrenomedullin and urinary thromboxane B2 help early categorizing of acute kidney injury in decompensated cirrhotic patients: A prospective cohort study

Author

Liu, Chih‐Wei, Huang, Chia‐Chang, Tsai, Hung‐Cheng, Su, Yen‐Bo, Huang, Shiang‐Fen, Lee, Kuei‐Chuan, Hsieh, Yun‐Cheng, Li, Tzu‐Hao, Tsai, Chang‐Youh, Chong, Lee‐Won, Ou, Shuo‐Ming, Yang, Ying‐Ying, Fan, Wen‐Chien, Hou, Ming‐Chih, Lin, Han‐Chieh, and Lee, Shou‐Dong

Published
2018
Full Text
View/download PDF

21. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naïve patients with compensated cirrhosis: real-world experience from Taiwan HCV registry

Author

Hung, Chao-Hung, primary, Chang, Te-Sheng, additional, Huang, Chung-Feng, additional, Kuo, Hsing-Tao, additional, Lo, Ching-Chu, additional, Huang, Chien-Wei, additional, Chong, Lee-Won, additional, Cheng, Pin-Nan, additional, Yeh, Ming-Lun, additional, Peng, Cheng-Yuan, additional, Cheng, Chien-Yu, additional, Huang, Jee-Fu, additional, Bair, Ming-Jong, additional, Lin, Chih-Lang, additional, Yang, Chi-Chieh, additional, Wang, Sih-Ren, additional, Hsieh, Tsai-Yuan, additional, Lee, Tzong-Hsi, additional, Lee, Pei-Lun, additional, Wu, Wen-Chih, additional, Lin, Chih-Lin, additional, Su, Wei-Wen, additional, Yang, Shengshun, additional, Wang, Chia-Chi, additional, Hu, Jui-Ting, additional, Mou, Lien-Juei, additional, Chen, Chun-Ting, additional, Huang, Yi-Hsiang, additional, Chang, Chun-Chao, additional, Huang, Jia-Sheng, additional, Chen, Guei-Ying, additional, Gao, Jian-Neng, additional, Tai, Chi-Ming, additional, Liu, Chun-Jen, additional, Lee, Mei-Hsuan, additional, Tsai, Pei-Chien, additional, Dai, Chia-Yen, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wan-Long, additional, Chen, Chiyi, additional, Tseng, Kuo-Chih, additional, and Yu, Ming-Lung, additional

Published
2022
Full Text
View/download PDF

23. Glecaprevir/ Pibrentasvir in the Treatment of Chronic Hepatitis C Patients – A Real-World Nationwide HCV Registry Program (TACR) in Taiwan

Author

Huang, Chung-Feng, primary, Kuo, Hsing-Tao, additional, Chang, Te-Sheng, additional, Lo, Ching-Chu, additional, Hung, Chao-Hung, additional, Huang, Chien-Wei, additional, Chong, Lee-Won, additional, Cheng, Pin-Nan, additional, Yeh, Ming-Lun, additional, Peng, Cheng-Yuan, additional, Cheng, Chien-Yu, additional, Huang, Jee-Fu, additional, Bair, Ming-Jong, additional, Lin, Chih-Lang, additional, Yang, Chi-Chieh, additional, Wang, Szu-Jen, additional, Hsieh, Tsai-Yuan, additional, Lee, Tzong-Hsi, additional, Lee, Pei-Lun, additional, Wu, Wen-Chih, additional, Lin, Chih-Lin, additional, Su, Wei-Wen, additional, Yang, Sheng-Shun, additional, Wang, Chia-Chi, additional, Hu, Jui-Ting, additional, Mo, Lein-Ray, additional, Chen, Chun-Ting, additional, Huang, Yi-Hsiang, additional, Chang, Chun-Chao, additional, Huang, Chia-Sheng, additional, Chen, Guei-Ying, additional, Kao, Chien-Neng, additional, Tai, Chi-Ming, additional, Liu, Chun-Jen, additional, Lee, Mei-Hsuan, additional, Tsai, Pei-Chien, additional, Dai, Chia-Yen, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wang-Long, additional, Chen, Chi-Yi, additional, Tseng, Kuo-Chih, additional, and Yu, Ming-Lung, additional

Published
2021
Full Text
View/download PDF

25. Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan

Author

Chen, Chi‐Yi, primary, Huang, Chung‐Feng, additional, Cheng, Pin‐Nan, additional, Tseng, Kuo‐Chih, additional, Lo, Ching‐Chu, additional, Kuo, Hsing‐Tao, additional, Huang, Yi‐Hsiang, additional, Tai, Chi‐Ming, additional, Peng, Cheng‐Yuan, additional, Bair, Ming‐Jong, additional, Chen, Chien‐Hung, additional, Yeh, Ming‐Lun, additional, Lin, Chih‐Lang, additional, Lin, Chun‐Yen, additional, Lee, Pei‐Lun, additional, Chong, Lee‐Won, additional, Hung, Chao‐Hung, additional, Huang, Jee‐Fu, additional, Yang, Chi‐Chieh, additional, Hu, Jui‐Ting, additional, Lin, Chih‐Wen, additional, Chen, Chun‐Ting, additional, Wang, Chia‐Chi, additional, Su, Wei‐Wen, additional, Hsieh, Tsai‐Yuan, additional, Lin, Chih‐Lin, additional, Tsai, Wei‐Lun, additional, Lee, Tzong‐Hsi, additional, Chen, Guei‐Ying, additional, Wang, Szu‐Jen, additional, Chang, Chun‐Chao, additional, Mo, Lein‐Ray, additional, Yang, Sheng‐Shun, additional, Wu, Wen‐Chih, additional, Huang, Chia‐Sheng, additional, Hsiung, Chou‐Kwok, additional, Kao, Chien‐Neng, additional, Tsai, Pei‐Chien, additional, Liu, Chen‐Hua, additional, Lee, Mei‐Hsuan, additional, Liu, Chun‐Jen, additional, Dai, Chia‐Yen, additional, Kao, Jia‐Horng, additional, Chuang, Wan‐Long, additional, Lin, Han‐Chieh, additional, and Yu, Ming‐Lung, additional

Published
2021
Full Text
View/download PDF

26. THU-217 - An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan

Author

Yu, Ming-Lung, Tai, Chi-Ming, Mou, Lien-Juei, Kuo, Hsing-Tao, Huang, Chung-Feng, Tseng, Kuo-Chih, Lo, Chingchu, Bair, Ming-Jong, Wang, Sih-Ren, Huang, Jee-Fu, Yeh, Ming-Lun, Chen, Chun-Ting, Tsai, Ming-Chang, Huang, Chien-Wei, Lee, Pei-Lun, Yang, Tzeng-Hue, Huang, Yi-Hsiang, Chong, Lee-Won, Chen, Chien-Lin, Yang, Chi-Chieh, Hung, Chao-Hung, Yang, Sheng-Shun, Cheng, Pin-Nan, Hsieh, Tsai-Yuan, Hu, Jui-Ting, Wu, Wen-Chih, Cheng, Chien-Yu, Chen, Guei-Ying, Chou, Kwok-Hsiung, Tsai, Wei-lun, Gao, Jian-Neng, Lin, Chih-Lang, Wang, Chia-Chi, Lin, Ta-Ya, Lin, Chih-Lin, Su, Wei-Wen, Lee, Tzong-Hsi, Chang, Te-Sheng, Liu, Chun-Jen, Dai, Chia-Yen, Chen, Chi-Yi, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wan-Long, and Peng, Cheng-Yuan

Published
2023
Full Text
View/download PDF

34. Relatively low risk and nonaggressive stage of colorectal cancer in individuals with negative baseline fecal immunochemical test results: A cohort study

Author

Chen, Meng‐Yu, Chang, Hung‐Chuen, Chong, Lee‐Won, Liu, Yuh‐Hwa, Sun, Cheuk‐Kay, Yang, Kuo‐Ching, and Lin, Yu‐Min

Abstract

Fecal immunochemical testing (FIT) is used as a screening tool because of its adequate sensitivity to detect colorectal cancer (CRC). Whether individuals with negative baseline FIT results have a low risk of CRC over a long period of follow‐up remains unclear. This retrospective cohort study investigated the characteristics of CRC in individuals with normal baseline FIT results. We retrospectively evaluated individuals who participated in the Taiwanese biennial FIT‐based CRC screening program at a single hospital between March 2010 and December 2017. Patients who had positive FIT results (≥30 μg Hb/g feces) and then underwent confirmatory colonoscopy were enrolled for further analysis. Patients were divided into two cohorts: target group (consisting of patients with negative FIT results in the baseline round, followed by positive FIT results and confirmatory colonoscopy in any one of the subsequent rounds) and reference group (consisting of patients with positive FIT results in the baseline round and confirmatory colonoscopy). The detection rate and characteristics of CRC were compared between two groups. A Pvalue of <.05 was considered statistically significant. A total of 51 789 individuals underwent 80 195 tests in four rounds of biennial FIT based CRC screening. The positivity rate of FIT was 8.2% (n = 6591). The colonoscopy compliance rate was 70.3% (n = 4635). From 4635 individuals, 1650 and 2985 were included in the target and reference groups, respectively. The CRC detection rate in the target and reference groups was 2.3% (38/1650) and 5.0% (149/2985), respectively (odds ratio = 0.45; 95% confidence interval = 0.31‐0.64). The CRC detection rate in the target group increased with screening intervals (Pfor trend = .001). After excluding patients with unknown stage, 35 patients in the target group and 130 patients in the reference group were included for subsequent analysis. Lesions were located mainly in the distal colon in both groups (82.9% [29/35] vs. 82.3% [107/130]; P= 1). The distribution of the CRC stage according to the seventh edition of the American Joint Committee on Cancer staging system in the target vs reference group was as follows: Stage 0: 48.6% vs 20.0%; Stage I: 11.4% vs 30.0%; Stage II: 20.0% vs 18.5%; Stage III: 17.1% vs 22.3%; and Stage IV: 2.9% vs 9.2%; (P= .008). CRC detection rate declined considerably if the baseline FIT result was negative. CRC detected in patients with negative baseline FIT results showed a high proportion of nonaggressive stage. Approximately 80% of CRCs were identified in the left‐sided colon, suggesting the limited ability of repetitive FIT to detect proximal CRC. These results support the benefits and necessity of consecutive FIT screening even when the baseline FIT result is negative.

Published
2021
Full Text
View/download PDF

35. Association of Periodontitis and Subsequent Depression

Author

Hsu, Chih-Chao, Hsu, Yi-Chao, Chen, Hsuan-Ju, Lin, Che-Chen, Chang, Kuang-Hsi, Lee, Chang-Yin, Chong, Lee-Won, and Kao, Chia-Hung

Subjects
Adult, Male, Depressive Disorder, Incidence, Observational Study, Comorbidity, Middle Aged, Risk Factors, Humans, Female, Prospective Studies, Periodontitis, Research Article, Aged, Proportional Hazards Models, Retrospective Studies
Abstract

Periodontitis is a systemic and chronic inflammatory disease associated with multiple physical conditions. Distress and depression are other problems affecting the progression of periodontitis. However, the causal relationship between depression and periodontitis has not been adequately investigated. This aim of this study was to determine the association between periodontitis and the subsequent development of depression. We identified 12,708 patients with newly diagnosed periodontitis from 2000 to 2005 and 50,832 frequency-matched individuals without periodontitis. Both groups were followed until diagnosed with depression, withdrawal from the National Health Insurance program, or the end of 2011. The association between periodontitis and depressio was analyzed using Cox proportional hazard regression models. The incidence density rate of depression was higher in the periodontitis group than in the nonperiodontitis group, with an adjusted hazard ratio of 1.73 (95% confidence interval 1.58–1.89) when adjusting for sex, age, and comorbidity. Cox models revealed that periodontitis was an independent risk factor for depression in patients, except for comorbidities of diabetes mellitus (DM), alcohol abuse, and cancer. Periodontitis may increase the risk of subsequent depression and was suggested an independent risk factor regardless of sex, age, and most comorbidities. However, DM, alcohol abuse, and cancer may prevent the development of subsequent depression because of DM treatment, the paradoxical effect of alcohol, and emotional distress to cancer, respectively. Prospective studies on the relationship between periodontitis and depression are warranted.

Published
2015

36. Serum adrenomedullin and urinary thromboxane B 2 help early categorizing of acute kidney injury in decompensated cirrhotic patients: A prospective cohort study

Author

Liu, Chih‐Wei, primary, Huang, Chia‐Chang, additional, Tsai, Hung‐Cheng, additional, Su, Yen‐Bo, additional, Huang, Shiang‐Fen, additional, Lee, Kuei‐Chuan, additional, Hsieh, Yun‐Cheng, additional, Li, Tzu‐Hao, additional, Tsai, Chang‐Youh, additional, Chong, Lee‐Won, additional, Ou, Shuo‐Ming, additional, Yang, Ying‐Ying, additional, Fan, Wen‐Chien, additional, Hou, Ming‐Chih, additional, Lin, Han‐Chieh, additional, and Lee, Shou‐Dong, additional

Published
2017
Full Text
View/download PDF

40. Depression and the Risk of Peptic Ulcer Disease

Author

Hsu, Chih-Chao, primary, Hsu, Yi-Chao, additional, Chang, Kuang-Hsi, additional, Lee, Chang-Yin, additional, Chong, Lee-Won, additional, Lin, Cheng-Li, additional, Shang, Chuin-Shee, additional, Sung, Fung-Chang, additional, and Kao, Chia-Hung, additional

Published
2015
Full Text
View/download PDF

41. Serum adrenomedullin and urinary thromboxane B2 help early categorizing of acute kidney injury in decompensated cirrhotic patients: A prospective cohort study.

Author

Liu, Chih‐wei, Huang, Chia‐chang, Tsai, Hung‐cheng, Su, Yen‐bo, Huang, Shiang‐fen, Lee, Kuei‐chuan, Hsieh, Yun‐cheng, Li, Tzu‐hao, Tsai, Chang‐youh, Chong, Lee‐won, Ou, Shuo‐ming, Yang, Ying‐ying, Fan, Wen‐chien, Hou, Ming‐chih, Lin, Han‐chieh, and Lee, Shou‐dong

Subjects
ADRENOMEDULLIN, THROMBOXANE synthesis, KIDNEY injuries, ACUTE kidney tubular necrosis, HEPATORENAL syndrome, THERAPEUTICS
Abstract

Aims: Increases in the systemic vasodilator adrenomedullin and the renal vasoconstrictors thromboxane A2 in cirrhotic patients are pathogenic factors for the development of functional acute kidney injury (AKI), including pre‐renal azotemia (PRA) and hepatorenal syndrome (HRS), which is associated with high mortality. This study aims to find biomarkers that can diagnose HRS at an early stage, to enable treatment as soon as possible. Methods: Acute decompensated cirrhotic patients who had been admitted to hospital were enrolled in this prospective cohort study. Blood and urinary samples were collected immediately after admission. In addition to initially categorizing AKI cases into PRA, acute tubular necrosis (ATN), and HRS groups, their final diagnosis was adjudicated by a nephrologist and a hepatologist who checked the corrected and misclassification rates for significant biomarkers. Results: The cut‐off values for serum adrenomedullin and urinary thromboxane B2 (TXB2), when used as predictors for functional AKI (adrenomedullin >283 pg/mL, urinary TXB2>978 [pg/mg urinary creatinine]), for HRS (adrenomedullin >428, urinary TXB2 >1604), and for good terlipressin plus albumin treatment responders (adrenomedullin >490, urinary TXB2 >1863), were observed. Patients with HRS who could be treated, due to high mortality, had significantly higher serum adrenomedullin and urinary TXB2 levels compared to HRS patients receiving standard treatment. In addition to predicting 60‐day mortality, a combination of these two markers further increased diagnostic accuracy for HRS among functional AKI. Conclusions: Prompt diagnosis of HRS by differentiating it from PRA and ATN can be achieved by using serum adrenomedullin and urinary TXB2 in acute decompensated cirrhotic patients. In combination with severe clinical courses, these two markers are useful to select HRS patients who cannot be treated. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

48. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals.

Author

Chen, Yen-Chun, Chang, Te-Sheng, Chen, Chien-Hung, Cheng, Pin-Nan, Lo, Ching-Chu, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Chung-Feng, Kuo, Hsing-Tao, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, and Huang, Jee-Fu

Subjects
CHRONIC hepatitis C, PLATELET count, ANTIVIRAL agents, HEPATITIS C
Abstract

To clarify the predictive factors of significant platelet count improvement in thrombocytopenic chronic hepatitis C (CHC) patients. CHC patients with baseline platelet counts of <150 × 103/μL receiving direct-acting antiviral (DAA) therapy with at least 12-weeks post-treatment follow-up (PTW12) were enrolled. Significant platelet count improvement was defined as a ≥10% increase in platelet counts at PTW12 from baseline. Platelet count evolution at treatment week 4, end-of-treatment, PTW12, and PTW48 was evaluated. This study included 4922 patients. Sustained virologic response after 12 weeks post-treatment was achieved in 98.7% of patients. Platelet counts from baseline, treatment week 4, and end-of-treatment to PTW12 were 108.8 ± 30.2, 121.9 ± 41.1, 123.1 ± 43.0, and 121.1 ± 40.8 × 103/μL, respectively. Overall, 2230 patients (45.3%) showed significant platelet count improvement. Multivariable analysis revealed that age (odds ratio (OR) = 0.99, 95% confidence interval (CI): 0.99–1.00, p = 0.01), diabetes mellitus (DM) (OR = 1.20, 95% CI: 1.06–1.38, p = 0.007), cirrhosis (OR = 0.66, 95% CI: 0.58–0.75, p < 0.0001), baseline platelet counts (OR = 0.99, 95% CI: 0.98–0.99, p < 0.0001), and baseline total bilirubin level (OR = 0.80, 95% CI: 0.71–0.91, p = 0.0003) were independent predictive factors of significant platelet count improvement. Subgroup analyses showed that patients with significant platelet count improvement and sustained virologic responses, regardless of advanced fibrosis, had a significant increase in platelet counts from baseline to treatment week 4, end-of-treatment, PTW12, and PTW48. Young age, presence of DM, absence of cirrhosis, reduced baseline platelet counts, and reduced baseline total bilirubin levels were associated with significant platelet count improvement after DAA therapy in thrombocytopenic CHC patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

49. Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry.

Author

Jang TY, Huang CF, Chang TS, Yang CC, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Kuo HT, and Yu ML

Abstract

Background/aims: Hepatitis C virus (HCV) eradication using antiviral agents augments the metabolic profile. Changes in glycated hemoglobin (HbA1c) levels in chronic hepatitis C patients who receive glecaprevir/pibrentasvir (GLE/PIB) remain elusive., Methods: Data from 2417 patients treated with GLE/PIB from the Taiwan HCV Registry were analyzed, and pretreatment HbA1c levels were compared with 3-months after the-end-of treatment levels. A sustained virological response (SVR) was defined as undetectable HCV RNA at 12 weeks after the end of treatment. A significant change in HbA1c level was defined as the 75th percentile of the change in the HbA1c level before and after treatment (decrement >0.2%)., Results: Serum HbA1c levels decreased significantly (6.0 vs 5.9%, P < 0.001). Post-treatment HbA1c levels decreased in all subgroups, except in non-SVR patients (5.7 vs 5.7%, P = 0.79). Compared to patients without significant HbA1c improvement (decrement >0.2%), those with HbA1c improvement were older (60.2 vs 58.6 years, P < 0.001), had higher serum creatinine levels (1.9 vs 1.6 mg/dL, P < 0.001), triglycerides (129.8 vs 106.2 mg/dL, P < 0.001), fasting glucose (135.8 vs 104.0 mg/dL, P < 0.001), and pretreatment HbA1c (7.1 vs 5.7%, P < 0.001) and had a higher proportion of male sex (57.9% vs 50.9%, P = 0.003), diabetes (84.3 vs 16.8%, P < 0.001), more advanced stages of chronic kidney disease (CKD) (15.7 vs 11.1 %, P < 0.001), anti-diabetic medication use (47.3 vs 16.4%, P < 0.001) and fatty liver (49.6 vs 38.3 %, P < 0.001). Multivariate analysis revealed that the factors associated with significant HbA1c improvement were age (odds ratio [OR]/95% confidence intervals [CI]: 1.01/1.00-1.02, P = 0.01), HbA1c level (OR/CI: 2.83/2.48-3.24, P < 0.001) and advanced CKD stages (OR/CI: 1.16/1.05-1.28, P = 0.004). If the HbA1c variable was not considered, the factors associated with significant HbA1c improvement included alanine aminotransferase level (OR/CI, 1.002/1.000-1.004, P = 0.01), fasting glucose level (OR/CI: 1.010/1.006-1.013, P < 0.001), and diabetes (OR/CI: 3.35/2.52-4.45, P < 0.001)., Conclusions: The HbA1c levels improved shortly after HCV eradication using GLE/PIB. The improvement in glycemic control can be generalized to all subpopulations, particularly in patients with a higher baseline HbA1c level or diabetes., Competing Interests: Declaration of competing interest Ming-Lung Yu. Research support from Abbvie, Abbott, BMS, Gilead, Merck and Roche. Consultant for Abbvie, Abbott, Ascletis, BMS, Gilead, J&J, Merck, Novartis, Pharmaessential and Roche. Speaker for Abbvie, Abbott, Ascletis, BMS, Gilead, Merck, Pharmaessential and Roche. Chung-Feng Huang. Speaker for Abbvie, BMS, Gilead, Merck, and Roche., (Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

50. Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program.

Author

Lu MY, Huang CF, Hung CH, Tai CM, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang SS, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin CL, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, and Yu ML

Subjects
Humans, Hepacivirus genetics, Artificial Intelligence, Antiviral Agents therapeutic use, RNA, Hepatitis C, Chronic complications, Hepatitis C, Chronic diagnosis, Hepatitis C, Chronic drug therapy, Hepatitis C, Liver Neoplasms
Abstract

Background/aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1-3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to investigate risk factors associated with DAA treatment failure. Machine-learning algorithms have been applied to discriminate subjects who may fail to respond to DAA therapy., Methods: We analyzed the Taiwan HCV Registry Program database to explore predictors of DAA failure in HCV patients. Fifty-five host and virological features were assessed using multivariate logistic regression, decision tree, random forest, eXtreme Gradient Boosting (XGBoost), and artificial neural network. The primary outcome was undetectable HCV RNA at 12 weeks after the end of treatment., Results: The training (n=23,955) and validation (n=10,346) datasets had similar baseline demographics, with an overall DAA failure rate of 1.6% (n=538). Multivariate logistic regression analysis revealed that liver cirrhosis, hepatocellular carcinoma, poor DAA adherence, and higher hemoglobin A1c were significantly associated with virological failure. XGBoost outperformed the other algorithms and logistic regression models, with an area under the receiver operating characteristic curve of 1.000 in the training dataset and 0.803 in the validation dataset. The top five predictors of treatment failure were HCV RNA, body mass index, α-fetoprotein, platelets, and FIB-4 index. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of the XGBoost model (cutoff value=0.5) were 99.5%, 69.7%, 99.9%, 97.4%, and 99.5%, respectively, for the entire dataset., Conclusion: Machine learning algorithms effectively provide risk stratification for DAA failure and additional information on the factors associated with DAA failure.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results